Micromet And AriZeke Pharmaceuticals, Inc. Enter Patent License Agreement For Single-Chain Antibody Technology
10/19/2005 5:10:37 PM
Micromet AG and Arizeke Pharmaceuticals Inc. have signed an agreement, under which Arizeke obtains a worldwide, non-exclusive license from Micromet to its single-chain antibody (SCA) patent portfolio for the development and commercialization of Arizeke’s proprietary drug delivery technology.
Under the terms of the agreement, Arizeke gains the right to create and commercialize SCAs targeting its proprietary pIgR antigen. In return, Micromet will receive an upfront payment and annual maintenance fees, as well as milestone and royalty payments from the development and commercialization of any resulting products.
comments powered by